Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2017, vol. 26, nr 6, September, p. 931–938

doi: 10.17219/acem/63005

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Soluble ST2 protein and hospitalizations due to worsening chronic heart failure during a one-year follow-up in a population with reduced ejection fraction

Karolina Wojtczak-Soska1,A,B,C,D, Agata Sakowicz2,B, Tadeusz Pietrucha2,E, Kamil Janikowski3,C,D, Małgorzata Lelonek3,A,C,E,F

1 Policlinic of Cardiology, Medical University of Lodz, Poland

2 Department of Medical Biotechnology, Medical University of Lodz, Poland

3 Department of Noninvasive Cardiology, Medical University of Lodz, Poland

Abstract

Background. Hospitalizations due to worsening chronic heart failure (CHF) are common. However, the relationship between a single measurement of soluble ST2 protein (sST2) and the necessity of hospitalization in CHF is still unclear.
Objectives. The aim of this study was to determine the association between a single measurement of sST2 concentration and hospitalizations due to worsening CHF during a one-year follow-up.
Material and Methods. The study involved 167 consecutive patients (mean age 63 years, 83% males) with CHF in stable NYHA classes I-III with left ventricular ejection fraction (LVEF) ≤ 45% (median 29.65%, range 13–45%). Fifty-six variables were analyzed (clinical factors, basic laboratory results on admission, standard 12-lead ECG, echocardiography and coronary arteriography results). Information about hospitalizations due to worsening CHF was obtained during telephone interviews conducted 12 months after discharge from the cardiac ward. In order to define factors associated with hospitalization, uniand multivariate regression analyses were performed.
Results. A total of 53 patients from the study group (38%) were hospitalized due to worsening CHF. They included a higher percentage of males (p = 0.042), higher concentrations of sST2 (p = 0.049), and glucose (p = 0.010). The multivariate analysis (for model χ2 = 17.235; p < 0.001) revealed that glucose and sST2 were independently associated with hospitalization due to worsening CHF during the 1-year observation (p < 0.001).
Conclusion. In patients with stable mild to moderate CHF with reduced EF, a single measurement of sST2 protein and glucose were independent variables for hospitalization due to worsening CHF over a 1-year follow-up period. The defined prognostic model including sST2 and fasting glucose better identified patients without HF-related hospitalizations.

Key words

prognosis, biomarkers, hospitalization, heart failure, ventricular dysfunction

References (35)

  1. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787–1847. DOI: 10.1093/eurheartj/ehs104.
  2. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med. 2009;360:1418–1428. DOI: 10.1056/NEJMsa0803563.
  3. Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll. Cardiol. 2009;53:557–573. DOI:10.1016/j.jacc.2008.10.041.
  4. Bueno H, Ross JS, Wang Y, et al. Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993–2006. JAMA. 2010;303:2141–2147. DOI:10.1001/jama.2010.748.
  5. Keenan PS, Normand SL, Lin Z, et al. An administrative claims measure suitable for profiling hospital performance on the basis of 30-day all cause readmission rates among patients with heart failure. Circ Cardiovasc Qual Outcomes. 2008;1:29–37. DOI: 10.1161/CIRCOUTCOMES.108.802686.
  6. Krumholz HM, Parent EM, Tu N, et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med 1997;157:99–104.
  7. Rehman SU, Mueller T, Januzzi JL Jr. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol. 2008;52:1458–1465. DOI: 10.1016/j.jacc.2008.07.042.
  8. Mueller T, Dieplinger B, Gegenhuber A, et al. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem. 2008;54:752–756. DOI: 10.1373/clinchem.2007.096560.
  9. Boisot S, Beede J, Isakson S, et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J Card Fail. 2008;14:732–738. DOI: 10.1016/j.cardfail.2008.06.415.
  10. Bayes-Genis A, Pascual-Figal D, Januzzi JL, et al. Soluble ST2 monitoring provides additional risk stratification for outpatients with decompensated heart failure. Rev Esp Cardiol. 2010;63:1171–1178.
  11. Manzano-Fernandez S, Mueller T, Pascual-Figal D, et al. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol. 2011;107:259–267. DOI: 10.1016/j.amjcard.2010.09.011.
  12. Pascual-Figal D, Manzano-Fernandez S, Boronat M, et al. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: Complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail. 2011;13:718–725. DOI: 10.1093/eurjhf/hfr047.
  13. Ky B, French B, McCloskey K, et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail. 2011;4:180–187. DOI: 10.1161/CIRCHEARTFAILURE.110.958223.
  14. Pascual-Figal DA, Ordoñez-Llanos J, Tornel PL. et al. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J Am Coll Cardiol. 2009;54:2174–2179. DOI: 10.1016/j.jacc.2009.07.041.
  15. Bayes-Genis A, de Antonio M, Galán A, et al. Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure. Eur J Heart Fail. 2012;14:32–38.
  16. Lupón J, de Antonio M, Galán A, et al. Combined use of the novel biomarkers high-sensitivity troponin T and ST2 for heart failure risk stratification vs conventional assessment. Mayo Clin Proc. 2013;88:234–243. DOI: 10.1093/eurjhf/hfr156.
  17. Wojtczak-Soska K, Sakowicz A, Pietrucha T, Lelonek M. Soluble ST2 protein in the short-term prognosis after hospitalisation in chronic systolic heart failure. Kardiol Pol. 2014;72:725–734. DOI: 10.5603/KP.a2014.0085.
  18. Sobczak S, Wojtczak-Soska K, Ciurus T, et al. Single sST2 protein measurement predicts adverse outcomes at 1-year followup in patients with chronic heart failure. Pol Arch Med Wewn. 2014;124:452–458.
  19. Ky B, French B, McCloskey K, et al. High-Sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail. 2011;4:180–187. DOI: 10.1161/CIRCHEARTFAILURE.110.958223.
  20. Januzzi JL, Pascual-Figal D, Daniels LB. ST2 Testing for chronic heart failure therapy monitoring: The International ST2 Consensus Panel Am J Cardiol. 2015;115:70B-5B. DOI: 10.1016/j.amjcard.2015.01.044.
  21. Felker GM, Fiuzat M, Thompson V, et al. Soluble ST2 in ambulatory patients with heart failure: Association with functional capacity and long-term outcomes. Circ Heart Fail. 2013;6:1172–1179. DOI: 10.1161/CIRCHEARTFAILURE.113.000207.
  22. Broch K, Ueland T, Nymo SH, et al. Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology. Eur J Heart Fail. 2012;14:268–277. DOI: 10.1093/eurjhf/hfs006.
  23. Anand IS, Rector TS, Kuskowski M, et al. Prognostic value of soluble ST2 in the Valsartan Heart Failure Trial. Circ Heart Fail. 2014;7:418–426. DOI: 10.1161/CIRCHEARTFAILURE.113.001036.
  24. Volpe M, Rubattu S, Burnett J Jr. Natriuretic peptides in cardiovascular diseases: current use and perspectives. Eur Heart J. 2014;35:419–425. DOI: 10.1093/eurheartj/eht466.
  25. Boerrigter G, Costello-Boerrigter LC, Burnett JC Jr. Natriuretic peptides in the diagnosis and management of chronic heart failure. Heart Fail Clin. 2009;5:501–514. DOI: 10.1016/j.hfc.2009.04.002.
  26. Cocco G, Jerie P. Assessing the benefits of natriuretic peptides-guided therapy in chronic heart failure. Cardiol J. 2015;22:5–11. DOI: 10.5603/CJ.a2014.0041.
  27. Wojtczak-Soska K, Sakowicz A, Pietrucha T, Lelonek M. Soluble ST2 protein in chronic heart failure is independentof traditional factors. Arch Med Sci. 2013;21:9,21–26. DOI: 10.5114/aoms.2013.33344.
  28. Januzzi JL, Pascual-Figal D, Daniels LB. ST2 Testing for chronic heart failure therapy. Am J Cardiol. 2015;115:70B–75B. DOI: 10.1016/j.amjcard.2015.01.044.
  29. Van de Veire NR, de Winter O, Gillebert TC, de Sutter J. Diabetes and impaired fasting glucose as predictors of morbidity and mortality in male coronary artery disease patients with reduced left ventricular function. Acta Cardiol. 2006;6:137–143.
  30. Gotsman I, Shauer A, Lotan C, Keren A. Impaired fasting glucose: A predictor of reduced survival in patients with heart failure. Eur J Heart Fail. 2014;16:1190–1198. DOI: 10.1002/ejhf.146.
  31. Habal MV, Liu PP, Austin PC, et al. Association of heart rate at hospital discharge with mortality and hospitalizations in patients with heart failure. Circ Heart Fail. 2014;7:12–20. DOI: 10.1161/CIRCHEARTFAILURE.113.000429.
  32. Gaggin HK, Szymonifka J, Bhardwaj A, et al. Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure. JACC Heart Fail. 2014;2:65–72. DOI: 10.1016/j.jchf.2013.10.005.
  33. Bayes-Genis A, de Antonio M, Vila J, et al. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. J Am Coll Cardiol. 2014;21(63):158–166. DOI: 10.1016/j.jacc.2013.07.087.
  34. Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J. 2013;34:2281–329. DOI: 10.1093/eurheartj/eht150.
  35. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2013;62:147–239. DOI: 10.1161/CIR.0b013e31829e8776.\
© Wroclaw Medical University